Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA7 | P43166 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11827223 | 0.85 | NQO1 (0.31) | NQO1TSHRTDP1 | |
| SCHEMBL292906 | 0.75 | XDH (0.36) | NQO1 | |
| SCHEMBL17134252 | 0.72 | ACACB (0.32) | NQO1 | |
| SCHEMBL22683407 | 0.72 | BRD4 (0.35) | NQO1 | |
| SCHEMBL21151 | 0.72 | — | — | |
| SCHEMBL122993 | 0.72 | LTA4H (0.53) | — | |
| SCHEMBL10971435 | 0.72 | APP (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3023792 | 0.71 | — | — | |
| SCHEMBL693618 | 0.71 | MAPT (0.47) | — | |
| SCHEMBL17103300 | 0.71 | NQO1 (0.30) | NQO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | claimed |
| EP-2099797-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2009-09-16 | — | — | EP | claimed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | claimed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | claimed |
| US-7868018-B2 | such as N [3-(2-(3-trifluoromethyl)-benzoylamino -[1,6]naphthyridin-3-yl)-2,4-dichloro-phenyl]-3-trifluoromethyl-benzamide, used as antiproliferative agents or for the treatment of autoimmune diseases and nervous system disorders | IRM LLC (BM) | 2011-01-11 | — | — | US | disclosed |
| EP-2099797-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2009-09-16 | — | — | EP | disclosed |
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-12-04 | — | — | US | disclosed |
| WO-2007021795-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-22 | — | — | WO | disclosed |
| US-4213994-A | Imidazolyl-(2)-carbinols having hypolipidemic action and process for preparing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300246-A1 | Compounds and Compositions as Protein Kinase Inhibitors | SGK2, BRSK2, FYN | NQO1 3998/4885TSHR 2320/4885TDP1 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.